Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 24, 2007 Brian Lawler	Neurocrine in the Green 2006 wasn't kind to the drug developer, but whatever happens with indiplon, Neurocrine's management deserves kudos for keeping investors well informed on the status of the drug and where the company stands as far as timelines go.
The Motley Fool June 16, 2010 Brian Orelli	Double-Digit Rise on Doubling Its Cash Neurocrine Biosciences is seeing a nice boost to its stock price today -- some 14% -- after Abbott Labs agreed to license its endometriosis treatment, elagolix, and any future follow-on products.
The Motley Fool July 18, 2006 Brian Lawler	Neurocrine's Tale of Woe After a couple of tough months, Neurocrine released its second-quarter results. This may be a great stock to own -- if you have the stomach to tolerate the risk.
The Motley Fool June 15, 2007 Brian Lawler	Neurocrine Moves Ahead Neurocrine resubmits a marketing application for its lead drug. Investors, take note.
The Motley Fool August 1, 2007 Brian Lawler	Neurocrine Awaits Its Destiny Neurocrine Biosciences updates investors on its plans for the rest of the year. A new marketing application was submitted for lead drug indiplon, following a negative FDA decision last year. Good news could come as soon as December 2007.
The Motley Fool May 8, 2007 Brian Lawler	Neurocrine Is Waking Up After being put to sleep for much of 2006 following an unexpected FDA smackdown on its lead drug, indiplon, shares of the biopharma have boosted over 50% higher versus its lows last year.
The Motley Fool June 23, 2006 Stephen D. Simpson	Neurocrine Biosciences: From Bad to Worse Pfizer's departure is a serious, though not fatal, blow to the biotech. While this story may yet have a happy ending, there's going to be a lot of nervous waiting between now and then. Investors, take note.
The Motley Fool June 23, 2010 Kris Eddy	Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems.
The Motley Fool November 6, 2006 Brian Lawler	Neurocrine's Big Headache Another clinical trial means a steep drop in share price, but the biopharmaceutical's not dead yet. Investors, take note.
The Motley Fool February 6, 2008 Brian Lawler	Neurocrine on the Upswing? Neurocrine Bioscience releases year-end numbers, and updates investors on the status of its top drugs.
The Motley Fool October 8, 2010 Brian D. Pacampara	Neurocrine Popped: What You Need to Know While the possibility of a big return exists, know that Neurocrine, as is the case with all baby biotechs, can plunge just as hard.
The Motley Fool September 5, 2006 Brian Lawler	Neurocrine Wakes Up Indiplon The biotech company announces new drug delays. Investors, take note.
The Motley Fool December 14, 2007 Brian Lawler	FDA Knocks Neurocrine a Knuckle Sandwich The FDA clobbers drugmaker Neurocrine with another delay.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool May 16, 2006 Stephen D. Simpson	The FDA Tries to Put Neurocrine to Sleep A surprisingly worded rejection sends two stocks skidding. But setbacks aren't always terminal. While it won't be easy, Neurocrine Biosciences and DOV Pharmaceuticals investors may just want to hang on.
The Motley Fool September 24, 2010 Brian Orelli	Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front.
The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool October 20, 2010 Matt Koppenheffer	Neurocrine Biosciences Shares Popped: What You Need to Know Shares of biotech Neurocrine Biosciences were up more than 10% in intraday trading on higher-than-average volume.
The Motley Fool March 9, 2004 David Nierengarten	Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool September 26, 2007 Brian Lawler	Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures.
BusinessWeek June 12, 2006 Catherine Arnst	Going From The Lab To Limbo The FDA has been delaying decisions on applications, and drugmakers are fuming.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool October 10, 2005 Stephen D. Simpson	The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool October 31, 2006 Brian Lawler	A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval.
The Motley Fool July 9, 2004 Phil Wohl	Abbott Labs Concocts Strong Q2 The drug maker reports earnings as expected and refines its third-quarter guidance.
The Motley Fool November 4, 2005 Stephen D. Simpson	A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals...
Bio-IT World July 11, 2002 Kevin Davies	Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool August 13, 2004 Charly Travers	Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
The Motley Fool April 19, 2006 Stephen D. Simpson	Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool July 21, 2006 Brian Lawler	Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady.
The Motley Fool August 29, 2006 Brian Lawler	More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note.
Pharmaceutical Executive January 1, 2006 Kenneth I. Kaitin	Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do.
The Motley Fool February 23, 2004 Brian Gorman	Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool June 27, 2008 Brian Lawler	Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal.
The Motley Fool April 26, 2006 Stephen D. Simpson	A Pain DOV Pharmaceutical Couldn't Cure A trial failure crushes the stock, but the game isn't over yet. Though there are risks aplenty here, there could still be value.
The Motley Fool October 26, 2004 Charly Travers	Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land?
The Motley Fool November 15, 2007 Charly Travers	John Edwards, Frozen Caveman Lawyer Presidential hopeful John Edwards' health-care plans could destroy drug research and development in this country by removing the patent protection on breakthrough drugs.
The Motley Fool May 28, 2004 Charly Travers	Don't Be a Biotech Gambler Stand on solid ground by learning to assess the value of future drug programs. Investing in biotechs -- rather than simply speculating in the sector -- requires a solid assessment of how much a company's drug programs could be worth.
The Motley Fool December 16, 2003 David Nierengarten	Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks.
The Motley Fool June 15, 2004 Brian Gorman	Abbott's Gambit Abbott Laboratories is making a high-stakes stand on drug pricing in a dispute that threatens to make hostages out of the pharmaceutical industry and its investors.
The Motley Fool August 16, 2006 S.J. Caplan	Abbott Labs' Latest Leaps Generating increased goodwill while potentially expanding its HIV drug market, together with marking progress in its new vascular stent business, proved to be a potent formula for lifting Abbott's shares early this week. Investors, take note.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.